knowledge -WSS

knowledge

author：Wikipedia 2025-09-07 04:07:47 - browse：68

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： CRISPR base editing slashes cholesterol levels in monkeys

explore

WSS

Organ aging and disease risk measured by new blood test

Medicare innovation center doesn’t save money, experts say

FDA investigates CAR

Despite FDA concern, risk that CAR

Despite FDA concern, risk that CAR

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

leisure time

knowledge

explore

How one medical school became remarkably diverse

Lawsuit highlights wrinkle for disputes over surprise medical bills

In age of alternative facts, a scholarly course on calling out crap

Stop Congress from blocking public access to science

Activists slam private health insurers over coverage restrictions

ReNAgade cuts staff seven months after raising $300 million

State Dept. review finds Biden bears some blame for Afghanistan failures

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Cancer drug shortages should be causing more outrage

Will the market for weight loss drugs really reach $100 billion?

hotspot

RSV injection headlines need to be accurate for good uptake

Rep. Raul Ruiz on the physician shortage and more

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Lawsuit highlights wrinkle for disputes over surprise medical bills

The EPA's new lead rule: How one expert crunched the numbers

Cigna, Humana reportedly in talks to merge

focus

entertainment

explore

knowledge